CN110177463B - 2-羟基苄胺在治疗和预防肺动脉高压中的应用 - Google Patents

2-羟基苄胺在治疗和预防肺动脉高压中的应用 Download PDF

Info

Publication number
CN110177463B
CN110177463B CN201780083516.9A CN201780083516A CN110177463B CN 110177463 B CN110177463 B CN 110177463B CN 201780083516 A CN201780083516 A CN 201780083516A CN 110177463 B CN110177463 B CN 110177463B
Authority
CN
China
Prior art keywords
glutamine
bmpr2
mutant
pmvecs
pah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780083516.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110177463A (zh
Inventor
J·P·费塞尔
L·J·罗伯茨
J·威斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN110177463A publication Critical patent/CN110177463A/zh
Application granted granted Critical
Publication of CN110177463B publication Critical patent/CN110177463B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780083516.9A 2016-11-15 2017-11-15 2-羟基苄胺在治疗和预防肺动脉高压中的应用 Active CN110177463B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
US62/422,486 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (2)

Publication Number Publication Date
CN110177463A CN110177463A (zh) 2019-08-27
CN110177463B true CN110177463B (zh) 2022-03-08

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083516.9A Active CN110177463B (zh) 2016-11-15 2017-11-15 2-羟基苄胺在治疗和预防肺动脉高压中的应用

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP4385576A3 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
WO2020154724A1 (en) 2019-01-25 2020-07-30 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
BR112022014876A2 (pt) * 2020-01-27 2022-12-13 Univ Vanderbilt Sequestradores de isolevuglandinas/isocetais que têm mitocôndria como alvo e usos dos mesmos
JP2023545304A (ja) * 2020-10-13 2023-10-27 ヴァンダービルト ユニバーシティー 腎傷害による腸リンパ管の乱れを予防する方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US8709434B2 (en) * 2006-11-13 2014-04-29 Pcb Associates, Inc. Compositions for inhibiting NADPH oxidase activity
CN103796648A (zh) * 2011-07-12 2014-05-14 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004224566A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
JP5132109B2 (ja) * 2006-09-01 2013-01-30 花王株式会社 一剤式染毛剤組成物
US8314015B2 (en) * 2010-07-14 2012-11-20 Sharp Laboratories Of America, Inc. Silicon surface modification for the electrochemical synthesis of silicon particles in suspension

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157501A1 (en) * 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US8709434B2 (en) * 2006-11-13 2014-04-29 Pcb Associates, Inc. Compositions for inhibiting NADPH oxidase activity
CN103796648A (zh) * 2011-07-12 2014-05-14 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
WO2015127163A1 (en) * 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oxidative injury is a common consequence of BMPR2 mutations;Kirk L.Lane et al;《Pulmonary Circulation》;20110331;第1卷(第1期);全文 *
Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans;Paulin R et al;《CELL METABOLISM》;20141104;第20卷(第5期);全文 *

Also Published As

Publication number Publication date
JP7383285B2 (ja) 2023-11-20
AU2017362328B2 (en) 2022-03-31
EP3541185A4 (en) 2020-06-24
WO2018093936A1 (en) 2018-05-24
EP3541185C0 (en) 2024-04-24
HUE067036T2 (hu) 2024-09-28
ES2981715T3 (es) 2024-10-10
PL3541185T3 (pl) 2024-08-12
AU2017362328A1 (en) 2019-06-27
JP2019536778A (ja) 2019-12-19
CN110177463A (zh) 2019-08-27
EP4385576A2 (en) 2024-06-19
EP3541185A1 (en) 2019-09-25
US20250381155A1 (en) 2025-12-18
US20190314302A1 (en) 2019-10-17
EP4385576A3 (en) 2024-09-04
EP3541185B1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
US20250381155A1 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
US20190365716A1 (en) Method for treating neurodegenerative diseases
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
Malkesman et al. Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants
Kim et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels
Fu et al. A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment
US20180344694A1 (en) Use of indole compounds to stimulate the immune system
Zhu et al. MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
Hong et al. A novel role of lactate: Promotion of Akt-dependent elongation of microglial process
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
JP2014156423A (ja) プロテアソーム活性化剤
CN103169694B (zh) 正丁烯基苯酞在制造用于治疗肝损伤和改善肝功能的药物中的用途及药物组合物
HK40107155A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
An et al. PDZK1 regulated by miR-145-5p protects against endothelial cell apoptosis and diabetic retinopathy by targeting mitochondrial function
HK40006700A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700B (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
CN119158028B (zh) 治疗白血病的药物组合及其应用
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
Alateeq Determination of the Mechanisms Regulating Mental Health Disorders in Chronic Obstructive Pulmonary Disease
US20220047550A1 (en) Compounds and methods for the treatment of degenerative disorders
Badimon Region-Specific Microglial Modulation of Neuronal Activity
US20200316096A1 (en) Combination of diet and drug therapy for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant